



Biotech Daily

Friday October 2, 2026

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH DOWN: IMPEDIMED UP 50%; PROTEOMICS DOWN 8%**
- * **BIOINTELECT VENTURER OPENS \$8.5m ROUND 2 APPLICATIONS**
- * **AUSBIOTECH: 3 WEEKS TO 2026 CONFERENCE**
- * **DR BOREHAM'S CRUCIBLE: PARADIGM BIOPHARMACEUTICALS**
- * **ARTRYA \$500k HUNSTVILLE HOSPITAL SALIX DEAL**
- * **ISLAND STARTS GALIDESIVIR PRODUCTION**
- * **ACRUX RECEIVES \$2m FEDERAL R&D TAX INCENTIVE**
- * **CLINUVEL POTENTIAL 2nd STRIKE, BOARD SPILL AGM**
- * **NANOSONICS 696k M-D RIGHTS, 33% DIRECTOR FEE HIKE AGM**
- * **ATOMO 3.1m 'IN-THE-MONEY' DIRECTOR OPTIONS AGM**
- * **DORSAVI REQUESTS 'CAPITAL RAISING' TRADING HALT**
- * **CAPITAL PROPERTY, BRINDABELLA SOUTHERN TAKE 16% OF BCAL**
- * **MAHNKENS, THREE FISH, SUNLORA TAKE 5% OF IMPEDIMED**
- * **JENCAY CAPITAL TAKES 17% OF ADHERIS**
- * **EBOS SELLS ADHERIS HOLDING**
- * **JAGEN, BORI LIBERMAN TAKE 11% OF CERYVYN**
- * **TRUSCREEN LOSES CEO MARTIN DILLON**
- * **NIV DAGAN REPLACES NEXALIS CHAIR SEAN WILLIAMS**
- * **MACH7 PROMOTES SHAWNI HADFIELD TO CFO**
- * **HARRY MILLER REPLACES OSTEOPORE CO-SEC JACK ROSAGRO**

MARKET REPORT

The Australian stock market was up 0.79 percent on Friday October 2, 2026, with the ASX200 up 67.7 points to 8,682.1 points. Eleven of the Biotech Daily Top 40 companies were up, 22 fell, six traded unchanged and one was untraded.

Yesterday's worst, Impedimed, was today's best, up 0.2 cents or 50 percent to 0.6 cents, with 15.3 million shares traded. Compumedics climbed 8.3 percent; Artrya improved 7.9 percent; Avita was up six percent; Optiscan and Racura were up more than three percent; Resonance rose 2.9 percent; with Neuren, Nanosonics, Polynovo, Resmed and Starpharma up by less than one percent.

Proteomics led the falls, down 1.0 cent or 7.7 percent to 12 cents, with 218,189 shares traded. Botanix and Imugene lost more than five percent; Alcidion, Amplia, Curvebeam and Dimerix fell more than four percent; Cochlear, Immutep, Imricor, Medical Developments and Saluda were down three percent or more; Cyclopharm, Pro Medicus and Telix shed more than two percent; Clinuvel, CSL, EBR, Mesoblast, Micro-X and Nova Eye were down more than one percent; with 4D Medical, Actinogen, Emvision and Orthocell down by less than one percent.

BIOINTELECT

Biointelect says expressions of interest for its round two 'Venturer', \$8.5 million funding program are open until October 16, 2026.

Biointelect said Biointelect Venturer was "Australia's national incubator for infectious disease innovation, helping promising Australian scientific innovators accelerate their path from discovery to impact".

The company said small to medium sized enterprises, research teams and innovators developing technologies for the prevention of infectious diseases were invited to apply.

Earlier this year, Biointelect said it would provide \$10.48 million to six Australian companies working on infectious disease projects in its first round (BD: Aug 31, 2026).

Today, the company said the program provided non-dilutive funding and tailored commercialization support "to help progress promising technologies towards commercial and investment readiness".

To apply, go to: <https://venturer.grantplatform.com/>.

AUSBIOTECH

Ausbiotech says the Ausmedtech, Ausbiotech Invest and its conference will be held at the Gold Coast Convention Centre, Queensland from October 20 to 23, 2026.

Ausbiotech said its conference and Ausmedtech would be delivered as "a connected program experience, allowing delegates to move across sessions and engage more broadly across Australia's life sciences ecosystem through a single registration pass"

The industry organization said Synthesis Bioventures managing-director Prof Andrew Wilks would deliver the Prof Nancy Millis Oration, sponsored by CSL, with Burns Service of Western Australia director and founder of Clinical Cell Culture (now Avita Medical) Prof Fiona Wood to deliver the Sanofi-sponsored Dr Irene Depaz Oration.

Ausbiotech said that Ausbiotech Invest will be held on October 20, 2026, with the Ausbiotech and Ausmedtech conferences to be held from October 21 to 23, 2026.

Pricing and registration is available at: <https://bit.ly/4dfV6KK>.

DR BOREHAM'S CRUCIBLE: PARADIGM BIOPHARMACEUTICALS

By TIM BOREHAM

ASX code: PAR

Share price: 24.5 cents (in suspension)

Shares on issue: 626,433,356

Market cap: \$153.5 million

Executive chair: Paul Rennie

Board: Mr Rennie, Amos Meltzer, Matthew Fry

Financials (year to June 30, 2026): revenue nil, other income \$8.1 million (up 14%), loss of \$56.3 million (previous deficit \$37.5 million), cash \$15.37 million (down 9%)

Identifiable major holders: Paul Rennie and related entities 3.32%, Mark van der Steeg 2.86%, Kzee Super Fund 1.98%, Evan Philip Clucas/Leanne Jane Weston 1.73%

Paradigm Biopharma has not quite been sealed in a corporate casket and interred. But Wednesday's appointment of voluntary administrators means it has one foot in the grave.

Can the knee osteoarthritis drug developer stage a Lazarus-like comeback with a tweaked clinical program and corporate purpose?

After all, the voluntary process is intended to enable thoughtful decision-making without pressure from nervous creditors.

Formally, the decision-making is in the hands of FTI Consulting's insolvency practitioners Christopher Pattinson and Hayden White, who assume responsibility for running the company and placating borrowers.

Their appointment follows last week's revelation that the company's pivotal phase III knee osteoarthritis trial had flopped. Strictly speaking, the study did not pass an interim 'futility' analysis and was discontinued.

Paradigm said the board had "formed the view that the company requires time to resolve the mismatch between current liabilities payable in the short term and the inherent long-term value of the intellectual property portfolio".

The company hopes for a deed of company arrangement (DOCA) to restructure its balance sheet and "assess a viable path" for the business.

"There is no certainty that a DOCA will be approved or implemented, or what the outcome will be for shareholders and creditors."

Futile pursuits

'Futility' is an emotive word often associated with war, cleaning a teenager's bedroom or arguing with a chatbot.

Now it's become all too synonymous with clinical trial setbacks and Paradigm became the latest victim with its study, Para-OA-012.

An independent data safety monitoring board (DSMB) deemed there to be no purpose in continuing the 538-patient study, which tested Paradigm's knee pain remedy with an anti-inflammatory mechanism of action.

In other words, the company failed the 'futility' test as determined by the DSMB.

Paradigm's legion of 'true believer' investors had keenly awaited the results – not to mention millions of knee osteoarthritis sufferers dependent on opioids.

While the voluntary administrators continue the post-mortem, the company's shares are cocooned in a share suspension.

PPS: Possible Pain Solution

It's all academic now, but the study road-tested Zilosul, Paradigm's name for injected pentosan polysulfate sodium (PPS), for mild to severe knee osteoarthritis.

Osteoarthritis affects around 530 million people globally, 32 million in the US. Knee OA accounts for 365 million of the worldwide tally.

PPS is an anti-inflammatory, heparin-like compound made from beechwood (hemicellulose). In the past, the drug has been used to treat a bladder condition and deep vein thrombosis. PPS has been used on dogs and horses, without any safety concerns. Currently, osteoarthritis commonly is treated with non-steroidal anti-inflammatory drugs or opioid-based painkillers, which are either ineffectual or undesirable.

Paradigm has an exclusive 25-year exclusive supply deal with Germany's Bene Pharmachem, the world's only approved PPS maker. Bene Pharmachem can do what it likes on the animal side, but Paradigm retains the rights to human applications.

Zilosul might be in the (very) slow lane now, but it had fast-track designation with the US Food and Drug Administration (FDA).

Paradigm over time

Paradigm was founded by Paul Rennie and Graeme Kaufman and listed on the ASX on August 18, 2015, having raised \$8 million at 35 cents apiece.

Mr Rennie was Mesoblast's head of product development. Mr Kaufman was CSL's chief financial officer through the plasma behemoth's privatization and was Mesoblast's vice president.

In November 2021, Mr Rennie ceded his chief executive role and continued as chair. But in November 2022 he returned to the CEO role.

In June last year, Paradigm acquired the private Proteobioactives Pty Ltd, an early-stage oral candidate for minor to mild osteoarthritis.

The purchase price was up to \$16.5 million, but only \$500,000 in cash up-front. The remainder depends on milestones.

Paradigm aimed to test PPS with Proteobioactive's COX-2 inhibitor, called Coxib. The idea was to improve drug 'bioavailability' - a shortcoming of many oral drugs.

Perhaps there's some residual value in this program?

Paradigm has exclusive rights to develop the combo for both knee osteoarthritis and the veterinary market (dogs and horses).

Where's the evidence?

Most of the sector's phase III trial flops have been a surprise, but in Paradigm's case investors were comforted by the results of no fewer than three phase II trials and screeds of 'world real' evidence.

The latter refers to about 700 patients - mainly footballers - who underwent the treatment via trials or expanded access schemes.

The first patient was dosed in 2016.

The three-phase II trials were Para-OA-005, Para-OA-008 and Para-OA-002. Para 005 achieved a primary endpoint of reduction in pain and improved function among its 121 subjects.

With 61 patients, Para-OA-008 measured the change in the synovial fluid biomarkers associated with pain, inflammation and osteoarthritis. disease, relative to placebo. In October 2023, Paradigm reported "clinically meaningful outcomes" at 365 days compared to placebo.

These included significant pain reduction and functional improvements and durable improvements in stiffness. The results were measured by the Western Ontario and McMaster Universities Osteoarthritis Index (Womac) questionnaire.

The company also reported reduced use of pain medication, with the placebo group resorting to paracetamol (or such) five times more than the treated group. The 600-patient Para-OA-002 trial confirmed the minimum effective dose for the phase III study.

The company also was encouraged by MRI imaging of 15 patients, suggesting 'functional' joint improvement.

This meant the drug not only reduced pain but halted the cartilage reduction at the epicentre of the problem.

What went wrong?

Er, good question.

The 538-patient, phase III study was being carried out across 57 sites, 41 in the US, 12 locally, three in Moldova and one in Hong Kong.

The outcome follows the DSMB's review of unblinded interim efficacy and safety data. The analysis took place when about 50 percent of participants had reached day 112 of treatment.

According to Paradigm, the problem stems from missing data, which raises the prospect of a giant snafu on the part of the company or the contract research organization.

We're not pointing fingers because we don't know.

"Operational challenges in the conduct of the study resulted in a significant amount of missing data, which has impacted the interim efficacy results," Paradigm said.

"Under the statistical analysis plan, missing data is imputed and this imputation impacted the efficacy outcome".

In other words: you can't fill in the gaps in the way unpopular polities do when they talk about the 'silent majority' of voters not expressing their preference.

Currently, the data remains blinded.

When it is unblinded, the company will review all the data including pain, function, safety and other pre-specified endpoints.

"The company continues to review the available data to obtain further information and better understand the nature and extent of that impact."

David Baker, founder of Adelaide firm Baker Young said "upwards of 30 percent" of the trial data appeared to be missing.

This "corrupted the overall read outs from approximately 50 percent of the total test participants"

He adds: "The FDA insists on a total data read out and nothing less" - which indeed is true.

Finances and performance

Among other housekeeping, management needs to assess trial wind-down costs and contractual obligations.

The decision to appoint a voluntary administrator was made with financier Obsidian Global Partners, which had extended a \$US27 million (\$A41 million) convertible note facility. Last Thursday, the company said it would return the latest (tranche four) drawdown of \$US2 million to Obsidian, with the related two million convertible notes cancelled.

“No premium, redemption amount, fee or other additional payment is payable by the company in connection with this arrangement,” Paradigm said.

Phew!

In the year to June 2026, Paradigm reported a net loss of \$56.3 million, compared with a \$37.56 million deficit previously.

As trial activity ramped up, research and development expenditure jumped to \$53.9 million, from \$17.7 million previously.

At the end of June, the company held cash of \$15.37 million, 8.6 percent lower.

During the year the company raised \$21.7 million: \$14 million in an institutional placement and \$7.74 million in a well-supported share purchase plan, all done at 19 cents a share. The offer included 117 million attached options exercisable at 23.75 cents apiece. Sadly, they were in the money until disaster struck.

This month, the company expects to pocket a \$7.62 million Federal Government Research and Development Tax Incentive.

The company was funded through the planned interim analysis and top-line primary endpoint readout.

Over the last year, Paradigm shares creaked between 45 cents (mid-October last year) and an all-time low of 14 cents on early June this year. The shares peaked at \$4.17 in January 2020, just as the pandemic hit.

Now, the stock is likely to worth one big fat donut.

Dr Boreham's diagnosis:

It's probably futile to mention this as readers know already, but Paradigm joins a disheartening list of ASX drug developers with late-stage trial flops.

For the record they were Opthea (now Cervyn, eye disease), Percheron (then Antisense, Duchenne muscular dystrophy), Immutep (lung cancer) and Cynata (knee OA and graft-versus-host-disease). Argenica and Syntara also have run into mid-stage trial whoopsies.

Like Tolstoy's unhappy families, each study ended unhappily for different reasons.

For instance, Opthea's and Percheron's control groups appeared to be unhelpfully effective.

In each case there was clear evidence of safety and efficacy from previous phase II studies.

So, something didn't translate to the bigger pivotal issues, or in each case they were victims of glitches in trial design and execution.

While Paradigm promises updates, investors and patients might never know what really went wrong.

To be honest, we get the impression that in most cases of failed trials the proponents still don't know, either.

Whether Paradigm's phase III flop proves to be a terminal roadblock remains to be seen.

Subject to the administrators' assessment and available resources, the company hopes to continue to review the study.

This process should take eight weeks.

An obvious question is why (perhaps) 30 percent of the trial data went missing.

"Over the next few weeks there will be a huge amount of investigation - it must be resolved," David Baker said ahead of the administrator appointment.

"This is a fabulous drug".

Management points out that it retains its intellectual property, which suggests Zilosul can be directed to other stuff in the anti-inflammatory field.

In the past, the company has mentioned heart failure, rheumatoid arthritis and respiratory distress syndrome.

Mr Baker notes the company had passed all previous FDA-compliant trials "with distinction".

"Hopefully, Paradigm can get back on track, to deliver a well-being drug which will change the life of so many people across the globe".

With the voluntary administrators sizing up the company through a dispassionate monetary lens, that outcome now looks, sadly, unlikely.

Disclosure: Dr Boreham is not a qualified medical practitioner and does not possess a doctorate of any sort. Does that make his life futile? Not at all!

ARTRYA

Artrya says it has a minimum \$500,000 contract to provide its Salix Coronary Anatomy and Coronary Plaque software to Alabama's Huntsville Hospital Health System.

In March last year, Artrya said that it had US Food and Drug Administration 510(k) clearance for its Salix Coronary Anatomy platform; (BD: Mar 28, 2025)

In August 2025, the company said it had FDA clearance for its Salix Coronary Plaque module for detecting high-risk plaque, an indicator of heart disease (BD: Aug 21, 2025).

Today, Salix said the five-year agreement was the first conversion of a study participant into a commercial customer and an important milestone in its US commercial strategy.

In 2022, Artrya said the Huntsville Heart Center would study the efficacy of its Salix computed tomography (CT) scan analysis software (BD: May 9, 2022).

Today, the company said that its Salix Coronary Anatomy would generate recurring software-as-a-service subscription revenue, with additional fee-per-scan revenue from coronary computed tomography angiography (CCTA) assessments performed with Salix Coronary Plaque and, following FDA clearance, Salix Coronary Flow.

Artrya said the terms of the agreement were commercial in confidence and include a monthly subscription fee and fee-per-scan.

Artrya chief executive officer John Konstantopoulos said the conversion of Huntsville Hospital Health from a study participant into a commercial customer was "an important milestone for Artrya's US strategy".

"Importantly, this is a multi-module commercial relationship," Mr Konstantopoulos said.

"The agreement establishes recurring [software as a service] revenue from Salix Coronary Anatomy, with additional fee-per-scan revenue from Salix Coronary Plaque and, following FDA clearance, Salix Coronary Flow," Mr Konstantopoulos said.

"With [Huntsville Hospital] Health joining Tanner Health, Northeast Georgia Health System and Cone Health, Artrya now has four US commercial customers," he said. "Our focus is on successfully deploying Salix across these customers while continuing to progress our ... relationships and broader US commercial activities."

Artrya was up 27 cents or 7.9 percent to \$3.70 with 3.9 million shares traded.

ISLAND PHARMACEUTICALS

Island says it has begun manufacturing galidesivir at Mumbai's PI Health Sciences for use in its emergency-use program for Bundibugyo Ebola in Uganda.

Earlier this year, Island said that with PI Health Sciences it began manufacturing galidesivir for use in pivotal studies of Marburg virus disease (BD: Jun 4, 2026).

Later, the company said it had "all government and regulatory approvals" for the compassionate use of galidesivir to treat infected patients in the ongoing Bundibugyo Ebola epidemic in Uganda (BD: Jul 7, 2026).

Today, Island said the first 5.0kg batch of galidesivir active pharmaceutical ingredient was expected to be completed by the end of this month.

The company said the following production it would "undertake the required finishing, vialing and packaging activities ahead of planned shipment to Uganda", with a second 5.0kg batch expected "by the end of November 2026".

Island said the additional supply was intended to support its "broader Ebola strategy and material for the company's planned pivotal Marburg non-human primate study under the US Food and Drug Administration's Animal Rule pathway".

Island managing-director Dr David Foster said that the 'good manufacturing practice' manufacture was "an important milestone".

Island was up two cents or 5.5 percent to 38.5 cents.

ACRUX

Acrux says it has received \$1,977,223 from the Australian Tax Office under the Federal Government's Research and Development Tax Incentive program.

Acrux said the incentive related to expenditure for the year to June 30, 2026.

The company said after full principal and interest repayment of the loan from Sydney's Radium Capital it would retain \$904,656 of the incentive.

In March, Acrux said it had a \$550,000 second RDTI Radium loan (BD: Mar 12, 2026).

Last year, Acrux said it had a \$400,000 loan from Radium at 17 percent interest a year, with funds for product development and working capital (BD: Nov 13, 2025).

Acrux was up 0.1 cents or 11.1 percent to one cent with 2.05 million shares traded.

CLINUVEL PHARMACEUTICALS

Clinuvel says its annual general meeting will vote on the remuneration report and, potentially, a second-strike board spill.

Last year, Clinuvel said its annual general meeting defeated the remuneration report and voted a first strike with 62.96 percent opposing the report (BD: Oct 17, 2025).

Under the Corporations Amendment (Improving Accountability on Director and Executive Remuneration) Act 2011 a company with a vote of 25 percent or more against the remuneration report in two successive annual meetings must vote on a board spill.

Today, the company said it benchmarked "remuneration to a comparable group of peers ... [and due to its] international operations and the sparsity of comparable companies in Australia" the peer group consisted of 28 US and 12 Australian companies.

The company said it stood "by the remuneration of our executives, including the managing-director [Dr Philippe Wolgen], and believe it is at appropriate levels".

Clinuvel did not state which companies were in the comparable peer group.

"In particular, the managing-director's [Dr Phillip Wolgen's] remuneration is below the median of the peer group," the company said.

According to its 2026 annual report Dr Wolgen was paid \$4,310,492, excluding shares.

Clinuvel said investors would vote on the re-election of directors Dr Pearl Grimes and Guy van Dievoet.

The meeting will be held at Arnold Bloch Leibler, Level 21, 333 Collins Street, Melbourne on November 6, 2026 at 10am (AEDT).

Clinuvel fell 15 cents or 1.8 percent to \$8.10.

NANOSONICS

Nanosonics says investors will vote on a 33.3 percent increase to the director fee pool and issue 696,196 rights to managing-director Michael Kavanagh.

Nanosonics said its annual general meeting would vote to issue Mr Kavanagh 70,833 service rights worth \$198,919 as the balance of his short-term incentive, vesting on August 31, 2027, as well as 625,363 performance rights as part of his long-term incentive, worth about \$1,756,206, in addition to his \$975,670 a year base pay.

Nanosonics said shareholders would vote to increase the aggregate non-executive directors' remuneration pool by 33.3 percent from \$1,200,000 to \$1,600,000.

Nanosonics said the meeting would vote to adopt the remuneration report, elect directors Sarah Butler, Dr Larry Marshall and Dr Tracey Batten and approve the equity plan.

The meeting will be held online and at Level 1, Building A, 7-11 Talavera Road, Macquarie Park, Sydney on November 4, 2026 at 10.30am (AEDT).

Nanosonics was up one cent or 0.35 percent to \$2.88 with 1.2 million shares traded.

ATOMO DIAGNOSTICS

Atomo says its annual general meeting will vote to issue 3,100,000 options to directors Dr Cheri Walker, Patrick Cook and Anthony May.

Atomo said investors would vote to issue interim chief executive officer Dr Cheri Walker 700,000 options, Mr Cook 1,400,000 options and Mr May 1,000,000 options, vesting on June 30, 2027, all exercisable at 1.7 cents each within two years.

The company said that “consistent with the desire to minimize cash expenditures, the board believes that in order to incentivize Mr Cook, Mr May and Dr Walker, in line with current market practices, options provide an appropriate and meaningful remuneration component to directors that is aligned with shareholder interests”.

Atomo said the options were in addition of Mr Cook and Mr May’s \$50,000 yearly pay, each, as well as Dr Walker’s \$445,000 salary.

The company said shareholders would vote to adopt the remuneration report, re-elect Mr Cook as a director, ratify the issue of placement shares and options, issue broker options, ratify the issue of shares and options under a share purchase plan, approve the employee incentive plan and approve the 10 percent placement facility.

The meeting will be held online on November 5, 2026 at 10am (AEDT).

Atomo was unchanged at 1.8 cents with 3.7 million shares traded.

DORSAVI

Dorsavi has requested a trading halt “for the purposes of considering and executing a proposed capital raising”.

Trading will resume on October 6, 2026, or on an earlier announcement.

Dorsavi last traded at 2.5 cents.

BCAL DIAGNOSTICS

Capital Property Corporation and Brindabella Southern say they increased their holding in Bcal from 53,639,844 shares (14.57%) to 57,405,545 shares (15.57%).

Canberra’s Capital Property Corporation Pty Ltd and Brindabella Southern Pty Ltd say they bought shares between January 27 and September 28, 2026, with the single largest purchase 621,152 shares on February 5 for \$71,575, or 11.5 cents a share.

Bcal fell 0.3 cents or 3.3 percent to 8.7 cents.

IMPEDIMED

Sydney’s Mahnken family, Three Fish Trust and Sunlora Pty Ltd say they have become a substantial shareholder in Impedimed with 189,381,435 shares, or 5.1708 percent.

Stephen Mahnken said with Dior Mahnken, Three Fish and Sunlora he bought shares between June 11 and September 25, 2026 at prices ranging from 0.4 cents to 1.0 cent.

Impedimed was up 0.2 cents or 50 percent to 0.6 cents with 15.3 million shares traded.

ADHERIS HEALTH (FORMERLY MEDADVISOR)

Jencay Capital Pty Ltd says it has increased its substantial shareholding in Adheris from 78,722,596 shares (12.34%) to 105,716,008 shares (16.57%).

Sydney’s Jencay said that between June 24 and September 29, 2026 it bought 26,993,412 shares for \$270,211, or 1.0 cent a share.

Adheris was unchanged at 1.3 cents.

ADHERIS HEALTH (FORMERLY MEDADVISOR)

Melbourne's Ebos Group says it has sold its 53,986,463 share-holding in Adheris. Ebos said that on October 1, 2026 it sold 26,993,412 shares for \$269,934, or one cent a share, to Jencay Capital "pursuant to a special crossing" and a further 26,993,411 shares "pursuant to 10 off-market transfer forms" for \$269,934, or one cent a share. Last year, Ebos Group said its 53,986,463 share-holding in Medadvisor was diluted from 9.81 percent to 8.65 percent (BD: May 16, 2025).

CERYVYN THERAPEUTICS (FORMERLY OPTHEA)

Jagen Nominees Pty Ltd says it has increased its substantial shareholding in Ceryvyn from 132,307,713 shares (9.66%) to 147,205,459 shares (10.76%). Melbourne's Jagen said that the shares were held by BHL Pension Fund Pty Ltd acting for the B Liberman Family and Boliber Pty Ltd. In 2018, Jagen said it became a substantial holder in the then Opthea with 18,202,068 shares (7.31%) and it was an investment vehicle for Bori Liberman (BD: Dec 4, 2018). Today, Jagen said that on October 1, 2026 it bought 14,897,746 shares in two on-market transactions for \$147,716, or one cent a share. Ceryvyn was unchanged at 1.1 cents with 7.8 million shares traded.

TRUSCREEN

Truscreen says chief executive officer Martin Dillon has resigned "for personal reasons", effective from October 31, 2026. Earlier this year, Truscreen said Mr Dillon had taken a three-month leave of absence to provide palliative care for his late spouse. Today, the company said Tony Ho would assume the responsibilities of executive chair and interim chief executive officer while it conducted a recruitment process. Mr Ho said that "on behalf of the board, I thank Mr Dillon for his significant contribution to Truscreen over many years, particularly in the past year, the opening of new markets in Central Asia, Indonesia, India, Malaysia, Thailand and greater Africa". "We respect his decision and recognize that his personal well-being is important," Mr Ho said. Truscreen was unchanged at one cent.

NEXALIS THERAPEUTICS (FORMERLY INHALERX)

Nexalis says Niv Dagan will replace chair Sean Williams who is "stepping down to focus on his other business commitments and on family matters". Nexalis said Mr Dagan had more than 20 years' experience in capital markets, corporate advisory and trading and was founding executive director of Peak Asset Management, had worked for HC Securities and Macquarie Bank and was currently Spenda chair as well as a director of Noviqtech and Terra Critical Minerals. According to his LinkedIn page, Mr Dagan held a Bachelor of Commerce from the University of Melbourne and a Master of Business Administration from Los Angeles' University of South California. In July, Mr Dagan said with 10 Bolivanos and Freedom Trader he had acquired 37,466,309 Nexalis shares or 14.81 percent of the company (BD Jul 30, 2026). The company said it thanked Mr Williams for his "contribution and leadership". Nexalis was untraded at 1.5 cents.

MACH7 TECHNOLOGIES

Mach7 says it has promoted interim chief financial officer Shawni Hadfield to permanent chief financial officer, effective immediately.

Earlier this year, Mach7 said it appointed commercial head Ms Hadfield as interim chief financial officer to replace Daniel Lee (BD: May 4, 2026).

Mach7 was unchanged at 23 cents.

OSTEOPORE

Osteopore says it has appointed Harry Miller to replace Jack Rosagro as company secretary, effective immediately.

Osteopore was up 0.1 cents or 33.3 percent to 0.4 cents with 1.1 million shares traded.